Brokers Offer Predictions for VRCA Q1 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Verrica Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.34) EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Price Performance

Verrica Pharmaceuticals stock opened at $0.54 on Thursday. The company has a market capitalization of $24.50 million, a price-to-earnings ratio of -0.29 and a beta of 1.44. Verrica Pharmaceuticals has a one year low of $0.54 and a one year high of $11.41. The company’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.11.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A number of hedge funds have recently bought and sold shares of VRCA. Verition Fund Management LLC bought a new stake in Verrica Pharmaceuticals during the third quarter valued at about $89,000. State Street Corp lifted its stake in shares of Verrica Pharmaceuticals by 13.5% in the third quarter. State Street Corp now owns 512,821 shares of the company’s stock valued at $744,000 after buying an additional 61,041 shares during the period. Jane Street Group LLC lifted its stake in shares of Verrica Pharmaceuticals by 106.5% in the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after buying an additional 36,028 shares during the period. XTX Topco Ltd bought a new stake in shares of Verrica Pharmaceuticals in the third quarter valued at about $335,000. Finally, Barclays PLC lifted its stake in shares of Verrica Pharmaceuticals by 404.6% in the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after buying an additional 25,130 shares during the period. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.